Evidence map›Paper›PMID 40895495›Full record

ArticleJCEM case reports2025

Unanticipated Adverse Events With Tirzepatide: Three Cases Underscoring the Importance of Postmarketing Monitoring.

Maria Colorado, Jose Gomez Miranda, Carlos E Arias-Morales

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maria ColoradoDepartment of Medicine, St. Barnabas Hospital, Bronx, NY 10457, USA.ORCID https://orcid.org/0009-0003-6193-9919
Jose Gomez MirandaSchool of Medicine, University of El Salvador, San Salvador 1101, El Salvador.ORCID https://orcid.org/0009-0009-3218-2359
Carlos E Arias-MoralesDepartment of Medicine, St. Barnabas Hospital, Bronx, NY 10457, USA.ORCID https://orcid.org/0000-0001-8223-1555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirzepatide (Zepbound), a novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, demonstrates an additive effect, significantly enhancing insulin secretion compared to administering each hormone separately. The case reports presented here, detailing palpitations, musculoskeletal pain, and headaches following tirzepatide administration, raise important questions about the drug's postmarketing safety profile.

Indexed as

adverse eventsdrug safetypostmarketing surveillancetirzepatide

Identifiers

PMID40895495
PMCPMC12395549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.